Brief: Cipher Pharmaceuticals Acquires Canadian Rights To U.S. FDA-Approved A 101 40% Topical Solution
06/04/2018 12:08
April 6 (Reuters) - Cipher Pharmaceuticals:
* CIPHER PHARMACEUTICALS ACQUIRES EXCLUSIVE CANADIAN RIGHTS
TO
U.S. FDA-APPROVED A-101 40% TOPICAL SOLUTION FROM ACLARIS
THERAPEUTICS
* CIPHER PHARMACEUTICALS INC - ACLARIS WILL RECEIVE AN
UPFRONT
PAYMENT OF US$1.0 MLN
Source text for Eikon: ID:nCNWQtYv4a
Further company coverage: CPH.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cipher Pharmaceuticals
See all newsBrief: Cipher Pharmaceuticals Receives Favourable Decision Confirming Arbitration Award
Canada's Cipher Pharma Q2 revenue falls on lower Natroba sales amid reduced Medicaid coverage
Canada Research Roundup: Altius Minerals, Cipher Pharmaceuticals, Suncor Energy
Canada's Cipher Pharmaceuticals Q1 net income jumps 135% on lower costs
Brief: Cipher Pharmaceuticals Q1 Net Income USD 6.163 Million